![]() |
市場調査レポート
商品コード
1380259
CRISPRおよびCas遺伝子の世界市場:2023-2030年Global CRISPR and Cas Genes Market 2023-2030 |
||||||
カスタマイズ可能
|
CRISPRおよびCas遺伝子の世界市場:2023-2030年 |
出版日: 2023年09月26日
発行: Orion Market Research
ページ情報: 英文 200 Pages
納期: 2~3営業日
|
世界のCRISPRおよびCas遺伝子市場は予測期間(2023-2030年)に13.5%のCAGRで成長すると予測されます。CRISPR-Casシステムは、世界中の分子生物学研究所で最も広く使用されているゲノム編集技術です。ゲノムターゲットの改良に伴うCRISPRベースのスクリーニングの採用拡大が、世界の市場の成長を支える主要因です。米国国立衛生研究所(NIH)によると、2020年4月、CRISPRベースのスクリーンは、RNAiなどのアプローチと比較して、汎用性、有効性が向上し、オフターゲット効果が低いことが実証されました。ゲノムワイドCRISPRスクリーンは、低ノイズ、高いノックアウト効率、最小限のオフターゲット効果で、大規模な機能喪失スクリーニングを実施するための強力なツールとして登場しました。それゆえ、市場プレーヤーはCRISPRゲノムワイドノックアウトライブラリーソリューションの導入にも注力しており、市場成長をさらに後押ししています。例えば、2023年10月、Cellecta, Inc.はゲノムワイドCRISPRニワトリおよびブタノックアウトライブラリーを発表しました。Cellecta, Inc.は、ニワトリ(Gallus gallus)とブタ(Sus scrofa)用の新しいプールされた単一モジュールのCRISPRゲノムワイドノックアウトライブラリーをリリースしました。この新しいライブラリーにより、1回の実験で遺伝子破壊の研究が可能になり、品種改良などが可能になります。
米国立衛生研究所(NIH)によると、2022年12月時点では、CRISPR/Cas9が主流(85%)で、TALEN(3.0%)がこれに続いた。植物ではイネ(13.0%)、トマト(7.0%)、小麦・大麦(3%)が最も研究されており、動物ではブタ(7.0%)、ニワトリ(2.0%)、ウシ(2.0%)が主に研究されています。
用途の中でも、ゲノムエンジニアリングのサブセグメントが世界のCRISPRおよびCas遺伝子市場でかなりのシェアを占めると予想されています。このセグメントの成長は、病原性変異の修正、がん免疫療法に不可欠な遺伝子の探索、臓器異種移植における重要な問題の解決などの分野でCRISPRおよびCas技術の影響力が高まっていることに起因しています。CRISPRおよびCas遺伝子製品の発売は、ゲノムを編集し、遺伝子の機能を変更するという急成長分野に特化した専用ソリューションを示すものです。例えば、2021年6月、QIAGENは遺伝子編集実験を迅速かつ簡便に解析するためのCRISPR専用製品を発売しました。同社はQIAprep& CRISPR KitとCRISPR Q-Primer Solutionsを発売し、研究者が編集された遺伝物質を比類のないスピードと効率で解析し、介入によって問題のDNA配列の機能がどのように変化したかを判断できるようにしました。
世界のCRISPRおよびCas遺伝子市場は、北米(米国、カナダ)、欧州(英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域)、アジア太平洋地域(インド、中国、日本、韓国、その他アジア地域)、世界のその他の地域(中東とアフリカ、南米)を含む地域別にさらに細分化されます。このうち北米は、単純な遺伝子ノックアウト、選択的ゲノム切断、オフターゲット切断の低減、ゲノム工学、より高い特異性など、強化された個々の製品が利用可能であることから、全世界の市場で突出したシェアを占めると予想されています。主な市場プレイヤーとしては、Addgene Inc.、Danaher Corp.、GenScript Biotech、Takara Bio Inc.、Thermo Fisher Scientific, Inc.などが挙げられます。
全地域の中で、アジア太平洋地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、新規治療法を開発するための研究開発への政府投資の増加が市場開拓を後押ししていることに起因します。例えば、2021年3月、日本のバイオテクノロジー企業であるセツローテックは、ダブリンを拠点とするERS Genomics社からCRISPR-Cas9技術の特許を取得しました。同社は、これらの先端技術を用いた動物モデルや細胞モデルの作製を進めています。このような取り組みにより、同地域におけるCRISPR技術の採用が促進され、収益創出にさらに貢献すると予測されます。
Title: Global CRISPR and Cas Genes Market Size, Share & Trends Analysis Report by Product Type (Vector-based Cas and DNA-free Cas), by Service Type (Cell Line Engineering, gRNA design, Microbial Gene Editing and DNA Synthesis), by Application (Genome Engineering, Disease Models, Functional Genomics and Other) and by End Users (Biotechnology Companies & Pharmaceutical, Academic and Government Research Institute and CROs),Forecast Period (2023-2030).
Global CRISPR and Cas genes market is anticipated to grow at a CAGR of 13.5% during the Forecast Period (2023-2030). CRISPR-Cas systems are the most widely used genome editing technology in molecular biology laboratories around the globe. The growing adoption of CRISPR-based screens with the improving genomic target is the key factor supporting the growth of the market globally. According to the National Institute of Health (NIH), in April 2020, CRISPR-based screens demonstrated improved versatility, efficacy, and lower off-target effects compared with approaches such as RNAi. Genome-wide CRISPR screen has emerged as a powerful tool for performing large-scale loss-of-function screens, with low noise, high knockout efficiency, and minimal off-target effects. Hence, the market players are also focusing on introducing CRISPR genome-wide knockout library solutions that further bolster the market growth. For instance, in October 2023, Cellecta, Inc. launched genome-wide CRISPR Chicken and Pig Knockout Libraries. Cellecta, Inc. released new pooled, single-module, CRISPR genome-wide knockout libraries for chicken (Gallus gallus) and pig (Sus scrofa). The new libraries allow the study of gene disruptions in a single experiment to enable improved breeding and more.
According to the National Institute of Health (NIH), in December 2022, CRISPR/Cas9 was the predominant tool (85%), followed by TALEN (3.0%). Rice (13.0%), tomato (7.0%), and wheat/barley (3%) were the most studied plants, whereas pig (7.0%), chicken (2.0%), and cow (2.0%) were the main animal species that were investigated.
The global CRISPR and Cas genes market is segmented on the product type, service type, and industry verticals. Based on the product type, the market is sub-segmented into vector-based Cas and DNA-free Cas. Based on the service type, the market is sub-segmented into cell line engineering, gRNA design, microbial gene editing, and DNA synthesis. Based on the application, the market is sub-segmented into genome engineering, disease models, functional genomics, and others. Further, based on end users, the market is sub-segmented into biotechnology companies and pharmaceutical, academic, and government research institutes and CROs. Among the service types, the microbial gene editing sub-segment is anticipated to hold a considerable share of the market owing to the rise in the development of CRISPR-Cas9 which can be used to edit genes within microorganisms. This editing process has a wide variety of applications including basic biological research, development of biotechnological products, and treatment of diseases. ICRISPR-Cas systems have also been used for the treatment of other hematologic diseases, such as sickle cell disease (SCD) and hemophilia B (HB). It is not only limited to the treatment of genetic disorders but also it has been found effective for the treatment of metastatic cancer.
Among the applications, the genome engineering sub-segment is expected to hold a considerable share of the global CRISPR and Cas genes market. The segmental growth is attributed to the growing influence of CRISPR and Cas technology in the field of correcting pathogenic mutations, searching for essential genes for cancer immunotherapy, and solving key problems in organ xenotransplantation. CRISPR and Cas genes product launch marks dedicated solutions specific to the fast-growing field of editing genomes and modifying gene function. For instance, in June 2021, QIAGEN launched dedicated CRISPR Products for rapid and simplified analysis of gene-editing experiments. The company launched QIAprep& CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
The global CRISPR and Cas genes market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the availability of enhanced individual products such as simple gene knockouts, selective genome cleavage, reduced off-target cutting, genome engineering, and higher specificity. The key market players include Addgene Inc., Danaher Corp., GenScript Biotech, Takara Bio Inc., Thermo Fisher Scientific, Inc., and others.
Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to increasing government investment in R&D to develop novel treatments is aiding in market expansion Japan and China are anticipated to support the region's growth. For instance, in March 2021, Japanese biotech company Setsuro Tech received a patent for CRISPR-Cas9 technology from Dublin-based ERS Genomics. The company is creating animal and cell models using these advanced technologies. Such initiatives are predicted to enhance CRISPR technology adoption in the region, further contributing towards revenue generation.
The major companies serving the CRISPR and Cas Genes market include: Danaher Corp., GenScript Biotech, Merck KGaA, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., GE Healthcare, Qiagen NV, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2020, Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. collaborated to provide Regeneron with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B.